從象徵參與到實質決策：西班牙 HTA 制度改革與全球 SIP/PLS 病友參與新浪潮

在醫療科技評估的領域中，如何讓「病友與照護者的真實生活經驗」真正影響新藥給付與醫療決策，一直是最核心的議題。近期由國際醫療科技評估學會病友與公民參與興趣小組主辦的線上研討會，完整呈現了西班牙最新的醫療科技評估制度轉型，並深入探討了「病友資訊摘要」如何打破技術門檻，打造多方平等的對話平台。

本文將為大家完整拆解這場研討會的三大講者分享重點，並特別針對研討會後深度追問與剖析的幾項關鍵實務議題進行全方位總整理！

一、三位主講者重點拆解：西班牙新法與全球 SIP 最佳實務

1. 西班牙病人組織平台：皇家法令下的 HTA 制度變革

講者：Pedro Carrascal 與 Lucía（代表 POP，涵蓋 50 個大型聯合會與約 2,000 個基層病友協會）

制度大轉型：西班牙近期通過全新的《皇家法令》，正式建立國家級醫療科技評估架構，並將評估範疇延伸至社會、經濟、道德等非臨床價值。

拒絕象徵性參與：POP 成功爭取將病友參與法制化，要求參與必須貫穿醫療科技評估的全生命週期與治理機構；同時促成西班牙國會啟動全球創舉的《病友組織法》立法與公開註冊制度。目前正等待「部長令」進一步確立具體評估方法、時程與意見權重。

2. BMS 全球團隊 / HTAi PCIG：SIP 的四大架構與全球推廣地圖

講者：José Díaz（HTAi PCIG 專案協同主持人）

標準化工具：解構 HTAi 制定之 SIP 標準範本（包含：評估背景、疾病負擔、新藥細節、術語辭典）。病友資訊摘要能將龐雜的審查檔案轉化為通俗語言，捕捉傳統臨床試驗難以體現的心理健康、照護者負擔與重返職場生產力等社會經濟價值。

全球推動地圖：病友資訊摘要已在蘇格蘭藥物委員會（發源地）、英國國家健康暨照護卓越研究院與澳洲藥品給付諮詢委員會常態落實；並正於台灣、新加坡、比利時、拉丁美洲與西班牙積極展開 Pilot 試辦！

3. 英國 NICE：12 週實務經驗與翻轉給付案例

講者：Ella FitPatrick（英國國家健康暨照護卓越研究院，民眾與社群團隊）

實質影響案例：分享英國國家健康暨照護卓越研究院在醫療科技評估各階段納入病友意見的成熟機制。例如在 Leber 氏遺傳性視網膜病變藥物評估中，病友組織於諮詢期補充了「照護者每月所需天數數據」，成功將原本不推薦給付的初審決策，翻轉為正面推薦給付。

流程重要優化：英國國家健康暨照護卓越研究院目前已處理超過 100 份病友資訊摘要，並進行重要流程調整——將病友團體的提交時間從 8 週延長至 12 週，讓病友團體能提前 4 週取得病友資訊摘要作為參考，以撰寫高質量的意見書。

二、深入追問與關鍵爭點完全剖析

這場研討會除了講者發表外，針對實務執行細節的追問更是精彩，以下整理幾項最具價值的關鍵解答：

Q1：病友資訊摘要審查會不會增加 HTA 機構的負擔？是否會延誤整體 HTA 流程？

審查負擔小：英國國家健康暨照護卓越研究院目前已將病友資訊摘要審查改由「技術團隊」在審查廠商整體檔案時併同辦理。技術團隊反饋指出，過程非常快速且「負擔並不沉重」。

時程無縫整合：英國國家健康暨照護卓越研究院將病友團體的提交時程從 8 週拉長至 12 週，雖然給予病友團體提前 4 週取得病友資訊摘要的優勢，但整體病友資訊摘要流程已完全無縫整合進英國國家健康暨照護卓越研究院的例行醫療科技評估體系中，未造成體系延宕。

Q2：藥企編寫病友資訊摘要到底要投入多少時間與人力？

廠商強烈支持：藥企對病友資訊摘要持強烈支持態度。根據英國國家健康暨照護卓越研究院收集的廠商反饋，編寫與提交病友資訊摘要「並未增加太多額外的時間」，因為病友資訊摘要是基於廠商已準備好的審查檔案進行轉譯與摘要，因此不會造成重大負擔。

Q3：病友資訊摘要由藥企撰寫，如何防止變成「商業行銷廣告」？

英國國家健康暨照護卓越研究院的防偏見三道防線：

技術團隊嚴格審查：技術團隊會審閱病友資訊摘要文字，若發現行銷、促銷用語或暗示「優於競爭對手」的字眼，會退回要求藥企修改。

嚴格撰寫指引：英國國家健康暨照護卓越研究院為藥企頒布明確的病友資訊摘要撰寫規範，界定可包含與禁止包含的內容。

資訊來源透明化：向病友團體明確標示病友資訊摘要來自藥企，提醒病友保持批判性思考，並結合自身數據交叉參照。

Q4：西班牙目前引入和執行病友資訊摘要的實際現況為何？

制度交會點：西班牙正處於《皇家法令》通過與歐盟《HTA 法規》實施的制度交會點。目前西班牙正在國際醫療科技評估學會國際架構下，結合 POP 與西班牙藥物局籌備辦理病友資訊摘要 Pilot 試辦專案，並等待後續部長令頒布具體細則。

Q5：簡明摘要與病友資訊摘要有何定義與差異？

概念與工具的關係：簡明摘要是廣義的「簡明摘要」總稱，泛指將高度專業的醫學語言轉譯為通俗文本；而病友資訊摘要則是國際醫療科技評估學會、蘇格蘭藥物委員會與英國國家健康暨照護卓越研究院在醫療科技評估領域中所定義與使用的「特定標準化範本與專案名稱」。

Q6：簡明摘要只能用在廠商提交的審查檔案嗎？能否用在 HTA 官方的評估報告？

最新延伸應用：在歐盟聯合臨床評估平行專案中，除了將廠商審查檔案轉譯為病友資訊摘要外，更特別推動將「最終由官方產出的聯合臨床評估臨床評估報告」轉譯為簡明摘要，確保病友與大眾能完全理解官方決策的依據與實證！

Q7：對照西班牙 RedETS 的實務調查，發現了什麼？

實務痛點印證：對照最新發表之 RedETS 調查數據，過去西班牙非藥品醫療科技評估的病友參與率僅 41%、85% 的參與時間占整體評估不到 25%，且面臨「語言艱深、角色不清晰、缺乏反饋」三大痛點。這正好印證了西班牙當前通過《皇家法令》與引進病友資訊摘要的必要性——唯有透過制度化與通俗工具，才能徹底改變傳統參與的結構性缺陷。

三、結語與對台灣 HTA 病友參與的啟示

從西班牙的法制化改革，到英國國家健康暨照護卓越研究院成熟的病友資訊摘要 12 週機制，再到歐盟聯合臨床評估將簡明摘要延伸至官方評估報告，全球醫療科技評估正在經歷一場「以病友為中心」的深遠變革。

值得令人振奮的是，台灣醫療科技評估團隊也已名列國際醫療科技評估學會全球病友資訊摘要 Pilot 合作聯盟之中！期待未來台灣在推動病友參與制度時，也能汲取西班牙與英國的實務經驗，透過標準化、透明化且通俗易懂的病友資訊摘要工具，讓台灣病友與照護者的聲音能在新藥給付決策中發揮真正的實質影響力！

English version below

From Symbolic Participation to Real Decision-Making: Spain’s HTA System Reform and the Global Wave of Patient Involvement in SIP/PLS

In the field of Health Technology Assessment (HTA), how to enable the “lived experience” of patients and caregivers to genuinely influence new drug reimbursement and medical decision-making has always been the core issue. A recent online seminar hosted by HTAi (International Society for Health Technology Assessment) Patient and Citizen Involvement Interest Group (PCIG) presented Spain’s latest HTA system transformation comprehensively and explored in depth how “Summary Information for Patients (SIP) / Plain Language Summary (PLS)” breaks down technical barriers and creates an equal dialogue platform for multiple stakeholders.

This article provides a complete breakdown of the three keynote speakers’ sharing highlights from this seminar, and particularly offers comprehensive analysis of several key practical issues discussed in-depth during Q&A sessions (including review burden, manufacturer workload, bias prevention mechanisms, Spain and global promotion status, differences between PLS and SIP, and the latest extended applications of EU JCA).

📌 Section 1: Three Keynote Speakers’ Key Takeaways: Spain’s New Law and Global SIP Best Practices

1. Spain’s Patient Organization Platform (POP): HTA System Reform Under Royal Decree

Speakers: Pedro Carrascal and Lucía (representing POP, covering 50 major federations and approximately 2,000 grassroots patient associations).

Major System Transformation: Spain recently passed a new Royal Decree (Real Decreto), formally establishing a national-level HTA evaluation framework and extending the assessment scope to non-clinical values including social, economic, and ethical considerations.

Rejecting Symbolic Participation: POP successfully advocated for legalizing patient participation, requiring participation to run throughout the entire HTA lifecycle and governance institutions. Simultaneously, POP promoted Spain’s Congress to initiate a global first—the Patient Organization Law and public registration system. Currently awaiting “Ministerial Order (Orden Ministerial)” to further establish concrete assessment methods, timelines (plazos), and opinion weights (pesos).

2. BMS Global Team / HTAi PCIG: The Four-Pillar Architecture of SIP and Global Promotion Map

Speaker: José Díaz (HTAi PCIG Project Co-Chair).

Standardized Tool: Deconstructing the SIP standard template established by HTAi (including: assessment background, disease burden, new drug details, terminology dictionary). SIP transforms complex review dossiers into plain language and captures socioeconomic values—such as mental health, caregiver burden, and return-to-work productivity—that traditional clinical trials struggle to demonstrate.

Global Promotion Map: SIP has been routinely implemented in Scotland (SMC, the originating location), United Kingdom (NICE), and Australia (PBAC); and is actively rolling out pilot projects in Taiwan (Taiwan HTA team participating in global alliance), Singapore, Belgium, Latin America, and Spain.

3. United Kingdom’s NICE: 12-Week Practical Experience and Reimbursement Decision Reversal Case

Speaker: Ella FitPatrick (NICE, Public and Community Team, United Kingdom).

Substantive Impact Case Study: Sharing NICE’s mature mechanisms for incorporating patient input at various HTA stages. For example, in the assessment of drugs for Leber Hereditary Optic Neuropathy (LHON), patient organizations supplemented “monthly data on days needed for caregiver support” during the consultation period, successfully reversing the initial assessment decision from non-recommendation to positive reimbursement recommendation.

Key Process Optimization: NICE has processed over 100 SIP documents and implemented important workflow adjustments—extending the patient group submission timeline from 8 weeks to 12 weeks, allowing patient groups to access SIP four weeks in advance as reference material for drafting high-quality opinion submissions.

🔍 Section 2: In-Depth Follow-Up Questions and Complete Analysis of Key Issues (Q&A Highlights)

Beyond the speakers’ presentations, the follow-up questions on practical implementation details were particularly enlightening. Below are several of the most valuable key responses:

Q1: Will SIP Review Increase the Review Burden of HTA Institutions? Will It Delay the Overall HTA Timeline?

Minimal Review Burden: UK NICE has already shifted SIP review to be conducted by “technical teams” while reviewing the manufacturer’s overall dossier. Technical teams have reported that the process is very fast and the burden is “not particularly burdensome.”

Seamless Timeline Integration: NICE extended the patient group submission timeline from 8 weeks to 12 weeks. Although this gives patient groups a 4-week advantage to access SIP in advance, the overall SIP workflow has been completely seamlessly integrated into NICE’s routine HTA evaluation system without causing any delay to the system.

Q2: How Much Time and Manpower Do Pharmaceutical Companies Need to Invest in Writing SIP?

Strong Manufacturer Support: Pharmaceutical companies strongly support SIP. Based on feedback collected by NICE from manufacturers, writing and submitting SIP “does not require much additional time,” because SIP is a translation and summary based on dossiers already prepared by manufacturers, and therefore does not create a significant burden.

Q3: Since SIP Is Written by Pharmaceutical Companies, How Can We Prevent It from Becoming “Commercial Marketing”? (Bias Prevention Mechanism)

NICE’s Three-Layer Bias Prevention Framework:

Strict Technical Team Review: Technical teams review SIP text and, if they discover marketing, promotional language, or implications of “superiority over competitors,” they request the pharmaceutical company to revise.

Strict Writing Guidelines: NICE issues clear SIP writing standards to pharmaceutical companies, defining what content can and cannot be included.

Information Source Transparency: Clearly indicating to patient groups that SIP comes from pharmaceutical companies and reminding them to maintain critical thinking while cross-referencing with their own data.

Q4: What Is the Actual Current Status of SIP Introduction and Implementation in Spain?

System Convergence Point: Spain is at the intersection of the Royal Decree implementation and the EU HTA Regulation (HTAR) implementation. Currently, Spain is preparing to conduct SIP pilot projects within the HTAi international framework, combining POP and Spain’s Medicines Agency (AEMPS), and awaiting subsequent Ministerial Order to establish concrete details.

Q5: What Are the Definitions and Differences Between PLS (Plain Language Summary) and SIP (Summary Information for Patients)?

Concept and Tool Relationship: PLS is a broad-sense term for “plain language summary,” referring generally to translating highly specialized medical language into plain text; while SIP is the “specific standardized template and project name” defined and used by HTAi, SMC, and NICE in the HTA field.

Q6: Can PLS Only Be Used in Manufacturer-Submitted Dossiers? Can It Be Applied to Official HTA Assessment Reports?

Latest Extended Application: In the EU Joint Clinical Assessment (JCA) parallel project, beyond translating manufacturer dossiers into SIP, there is special promotion to translate “the final clinically assessed JCA Report produced by official bodies into PLS,” ensuring that patients and the public can fully understand the rationale and evidence behind official decisions.

Q7: What Was Discovered When Compared with the Practical Survey from Spain’s RedETS (Published in 2026)?

Confirmation of Practical Pain Points: Comparing with the latest RedETS survey data published in IJTAHC, Spain’s non-pharmaceutical HTA had a patient involvement rate of only 41% in the past, with 85% of involvement time accounting for less than 25% of the overall assessment period, and faced three major pain points: “difficult language, unclear roles, and lack of feedback.” This precisely validates the necessity of Spain’s passage of the Royal Decree and introduction of SIP—only through institutionalization and plain language tools can the structural defects of traditional participation be fundamentally transformed.

💡 Section 3: Conclusion and Implications for Taiwan’s HTA Patient Involvement

From Spain’s legislative reform, to UK NICE’s mature 12-week SIP mechanism, to the EU JCA extending PLS to official assessment reports, the global HTA is undergoing a profound “patient-centered” transformation.

Encouraging news is that the Taiwan HTA team is already listed in the HTAi global SIP Pilot cooperation alliance. We look forward to Taiwan learning from Spain and UK’s practical experiences in advancing patient involvement systems in the future, and using the standardized, transparent, and plain language SIP tool to enable Taiwan’s patients and caregivers’ voices to have true substantive impact on new drug reimbursement decisions.